Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.

Detalles Bibliográficos
Autores principales: Wallis, Christopher J. D., Klaassen, Zachary, Jackson, William C., Dess, Robert T., Reichert, Zachery R., Sun, Yilun, Spratt, Daniel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144926/
https://www.ncbi.nlm.nih.gov/pubmed/34028551
http://dx.doi.org/10.1001/jamanetworkopen.2021.10950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144926/
https://www.ncbi.nlm.nih.gov/pubmed/34028551
http://dx.doi.org/10.1001/jamanetworkopen.2021.10950

Ejemplares similares